nach oben

Journal of Neuro-Oncology

Erschienen in:

01.02.2016 | Topic Review

How to train glioma cells to die: molecular challenges in cell death

verfasst von: Jeffrey Wojton, Walter Hans Meisen, Balveen Kaur

Erschienen in: Journal of Neuro-Oncology | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Abstract

The five-year survival rate for patients with malignant glioma is less than 10 %. Despite aggressive chemo/radiotherapy these tumors have remained resistant to almost every interventional strategy evaluated in patients. Resistance to these agents is attributed to extrinsic mechanisms such as the tumor microenvironment, poor drug penetration, and tumoral heterogeneity. In addition, genetic and molecular examination of these tumors has revealed defective apoptotic regulation, enhanced pro-survival autophagy signaling, and a propensity for necrosis that aids in the adaptation to environmental stress and resistance to treatment. The combination of extrinsic and intrinsic hallmarks in glioma contributes to the multifaceted resistance to traditional anti-tumor agents. Here we describe the biology of the disease relevant to therapeutic resistance, with a specific focus on molecular deregulation of cell death pathways. Emerging studies investigating the targeting of these pathways including BH3 mimetics and autophagy inhibitors that are being evaluated in both the preclinical and clinical settings are discussed. This review highlights the pathways exploited by glioblastoma cells that drive their hallmark pro-survival predisposition and makes therapy development such a challenge.

Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A et al (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114(2):97–109PubMedPubMedCentralCrossRef

Jiang YG, Peng Y, Koussougbo KS (2011) Necroptosis: a novel therapeutic target for glioblastoma. Med Hypotheses 76(3):350–352PubMedCrossRef

Tait SW, Green DR (2010) Mitochondria and cell death: outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol 11(9):621–632PubMedCrossRef

Chipuk JE, Moldoveanu T, Llambi F, Parsons MJ, Green DR (2010) The BCL-2 family reunion. Mol Cell 37(3):299–310PubMedPubMedCentralCrossRef

Cartron PF, Loussouarn D, Campone M, Martin SA, Vallette FM (2012) Prognostic impact of the expression/phosphorylation of the BH3-only proteins of the BCL-2 family in glioblastoma multiforme. Cell Death Dis 3:e421PubMedPubMedCentralCrossRef

Strik H, Deininger M, Streffer J, Grote E, Wickboldt J, Dichgans J et al (1999) BCL-2 family protein expression in initial and recurrent glioblastomas: modulation by radio-chemotherapy. J Neurol Neurosurg Psychiatry 67(6):763–768PubMedPubMedCentralCrossRef

Qiu B, Wang Y, Tao J, Wang Y (2012) Expression and correlation of Bcl-2 with pathological grades in human glioma stem cells. Oncol Rep 28(1):155–160PubMed

Nagane M, Levitzki A, Gazit A, Cavenee WK, Huang HJ (1998) Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases. Proc Natl Acad Sci USA 95(10):5724–5729PubMedPubMedCentralCrossRef

Zhu H, Cao X, Ali-Osman F, Keir S, Lo HW (2010) EGFR and EGFRvIII interact with PUMA to inhibit mitochondrial trans-localization of PUMA and PUMA-mediated apoptosis independent of EGFR kinase activity. Cancer Lett 294(1):101–110PubMedPubMedCentralCrossRef

10.

Stegh AH, Kim H, Bachoo RM, Forloney KL, Zhang J, Schulze H et al (2007) Bcl2L12 inhibits post-mitochondrial apoptosis signaling in glioblastoma. Genes Dev 21(1):98–111PubMedPubMedCentralCrossRef

11.

Stegh AH, Kesari S, Mahoney JE, Jenq HT, Forloney KL, Protopopov A et al (2008) Bcl2L12-mediated inhibition of effector caspase-3 and caspase-7 via distinct mechanisms in glioblastoma. Proc Natl Acad Sci USA 105(31):10703–10708PubMedPubMedCentralCrossRef

12.

Stegh AH, Brennan C, Mahoney JA, Forloney KL, Jenq HT, Luciano JP et al (2010) Glioma oncoprotein Bcl2L12 inhibits the p53 tumor suppressor. Genes Dev 24(19):2194–2204PubMedPubMedCentralCrossRef

13.

Tagscherer KE, Fassl A, Campos B, Farhadi M, Kraemer A, Bock BC et al (2008) Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins. Oncogene 27(52):6646–6656PubMedCrossRef

14.

Manero F, Gautier F, Gallenne T, Cauquil N, Gree D, Cartron PF et al (2006) The small organic compound HA14-1 prevents Bcl-2 interaction with Bax to sensitize malignant glioma cells to induction of cell death. Cancer Res 66(5):2757–2764PubMedCrossRef

15.

Dodou K, Anderson RJ, Small DA, Groundwater PW (2005) Investigations on gossypol: past and present developments. Expert Opin Investig Drugs 14(11):1419–1434PubMedCrossRef

16.

Wagenknecht B, Glaser T, Naumann U, Kugler S, Isenmann S, Bahr M et al (1999) Expression and biological activity of X-linked inhibitor of apoptosis (XIAP) in human malignant glioma. Cell Death Differ 6(4):370–376PubMedCrossRef

17.

Chakravarti A, Noll E, Black PM, Finkelstein DF, Finkelstein DM, Dyson NJ et al (2002) Quantitatively determined survivin expression levels are of prognostic value in human gliomas. J Clin Oncol 20(4):1063–1068PubMedCrossRef

18.

Ziegler DS, Wright RD, Kesari S, Lemieux ME, Tran MA, Jain M et al (2008) Resistance of human glioblastoma multiforme cells to growth factor inhibitors is overcome by blockade of inhibitor of apoptosis proteins. J Clin Investig 118(9):3109–3122PubMedPubMedCentralCrossRef

19.

Chakravarti A, Zhai GG, Zhang M, Malhotra R, Latham DE, Delaney MA et al (2004) Survivin enhances radiation resistance in primary human glioblastoma cells via caspase-independent mechanisms. Oncogene 23(45):7494–7506PubMedCrossRef

20.

Fulda S, Wick W, Weller M, Debatin KM (2002) Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med 8(8):808–815PubMed

21.

Wagner L, Marschall V, Karl S, Cristofanon S, Zobel K, Deshayes K et al (2013) Smac mimetic sensitizes glioblastoma cells to Temozolomide-induced apoptosis in a RIP1- and NF-kappaB-dependent manner. Oncogene 32(8):988–997PubMedCrossRef

22.

Begg AC, Stewart FA, Vens C (2011) Strategies to improve radiotherapy with targeted drugs. Nat Rev Cancer 11(4):239–253PubMedCrossRef

23.

Venur VA, Peereboom DM, Ahluwalia MS (2015) Current medical treatment of glioblastoma. Cancer Treat Res 163:103–115PubMedCrossRef

24.

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996PubMedCrossRef

25.

Kondo N, Takahashi A, Ono K, Ohnishi T (2010) DNA damage induced by alkylating agents and repair pathways. J Nucleic Acids 2010:543531PubMedPubMedCentralCrossRef

26.

Weller M, Stupp R, Reifenberger G, Brandes AA, van den Bent MJ, Wick W et al (2010) MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol 6(1):39–51PubMedCrossRef

27.

Barazzuol L, Jena R, Burnet NG, Meira LB, Jeynes JC, Kirkby KJ et al (2013) Evaluation of poly (ADP-ribose) polymerase inhibitor ABT-888 combined with radiotherapy and temozolomide in glioblastoma. Radiat Oncol 8:65PubMedPubMedCentralCrossRef

28.

Lin F, de Gooijer MC, Roig EM, Buil LC, Christner SM, Beumer JH et al (2014) ABCB1, ABCG2, and PTEN determine the response of glioblastoma to temozolomide and ABT-888 therapy. Clin Cancer Res Off J Am Assoc Cancer Res 20(10):2703–2713CrossRef

29.

Tentori L, Leonetti C, Scarsella M, D’Amati G, Vergati M, Portarena I et al (2003) Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma. Clin Cancer Res Off J Am Assoc Cancer Res 9(14):5370–5379

30.

Donawho CK, Luo Y, Luo Y, Penning TD, Bauch JL, Bouska JJ et al (2007) ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res Off J Am Assoc Cancer Res 13(9):2728–2737CrossRef

31.

Levine B, Kroemer G (2008) Autophagy in the pathogenesis of disease. Cell 132(1):27–42PubMedPubMedCentralCrossRef

32.

Liu EY, Ryan KM (2012) Autophagy and cancer–issues we need to digest. J Cell Sci 125(Pt 10):2349–2358PubMedCrossRef

33.

White E, DiPaola RS (2009) The double-edged sword of autophagy modulation in cancer. Clin Cancer Res 15(17):5308–5316PubMedPubMedCentralCrossRef

34.

Fan QW, Cheng C, Hackett C, Feldman M, Houseman BT, Nicolaides T et al (2010) Akt and autophagy cooperate to promote survival of drug-resistant glioma. Sci Signal 3(147):ra81PubMedPubMedCentralCrossRef

35.

Shen J, Zheng H, Ruan J, Fang W, Li A, Tian G et al (2013) Autophagy inhibition induces enhanced proapoptotic effects of ZD6474 in glioblastoma. Br J Cancer 109(1):164–171PubMedPubMedCentralCrossRef

36.

Gammoh N, Lam D, Puente C, Ganley I, Marks PA, Jiang X (2012) Role of autophagy in histone deacetylase inhibitor-induced apoptotic and nonapoptotic cell death. Proc Natl Acad Sci USA 109(17):6561–6565PubMedPubMedCentralCrossRef

37.

Li Y, Zhu H, Zeng X, Fan J, Qian X, Wang S et al (2013) Suppression of autophagy enhanced growth inhibition and apoptosis of interferon-beta in human glioma cells. Mol Neurobiol 47(3):1000–1010PubMedCrossRef

38.

Ge PF, Zhang JZ, Wang XF, Meng FK, Li WC, Luan YX et al (2009) Inhibition of autophagy induced by proteasome inhibition increases cell death in human SHG-44 glioma cells. Acta Pharmacol Sin 30(7):1046–1052PubMedPubMedCentralCrossRef

39.

Chen Y, Meng D, Wang H, Sun R, Wang D, Wang S, et al (2014) VAMP8 facilitates cellular proliferation and temozolomide resistance in human glioma cells. Neuro Oncol 17(3):407–418

40.

Cho HY, Wang W, Jhaveri N, Lee DJ, Sharma N, Dubeau L et al (2014) NEO212, temozolomide conjugated to perillyl alcohol, is a novel drug for effective treatment of a broad range of temozolomide-resistant gliomas. Mol Cancer Ther 13(8):2004–2017PubMedCrossRef

41.

Curry RC, Dahiya S, Alva Venur V, Raizer JJ, Ahluwalia MS (2015) Bevacizumab in high-grade gliomas: past, present, and future. Expert Rev Anticancer Ther 15(4):387–397PubMedCrossRef

42.

Gilbert MR, Sulman EP, Mehta MP (2014) Bevacizumab for newly diagnosed glioblastoma. New Engl J Med 370(21):2048–2049PubMedCrossRef

43.

Chinot OL, Wick W, Cloughesy T (2014) Bevacizumab for newly diagnosed glioblastoma. New Engl J Med 370(21):2049PubMedCrossRef

44.

Hu YL, DeLay M, Jahangiri A, Molinaro AM, Rose SD, Carbonell WS et al (2012) Hypoxia-induced autophagy promotes tumor cell survival and adaptation to antiangiogenic treatment in glioblastoma. Cancer Res 72(7):1773–1783PubMedPubMedCentralCrossRef

45.

Golden EB, Cho HY, Jahanian A, Hofman FM, Louie SG, Schonthal AH et al (2014) Chloroquine enhances temozolomide cytotoxicity in malignant gliomas by blocking autophagy. Neurosurg Focus 37(6):E12PubMedCrossRef

46.

Rosenfeld MR, Ye X, Supko JG, Desideri S, Grossman SA, Brem S et al (2014) A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme. Autophagy 10(8):1359–1368PubMedPubMedCentralCrossRef

47.

Alonso MM, Jiang H, Yokoyama T, Xu J, Bekele NB, Lang FF et al (2008) Delta-24-RGD in combination with RAD001 induces enhanced anti-glioma effect via autophagic cell death. Mol Ther 16(3):487–493PubMedCrossRef

48.

Zong WX, Thompson CB (2006) Necrotic death as a cell fate. Genes Dev 20(1):1–15PubMedCrossRef

49.

Stegh AH, Chin L, Louis DN, DePinho RA (2008) What drives intense apoptosis resistance and propensity for necrosis in glioblastoma? A role for Bcl2L12 as a multifunctional cell death regulator. Cell Cycle 7(18):2833–2839PubMedCrossRef

50.

Flannery T, McQuaid S, McGoohan C, McConnell RS, McGregor G, Mirakhur M et al (2006) Cathepsin S expression: an independent prognostic factor in glioblastoma tumours—a pilot study. Int J Cancer J Int Du cancer 119(4):854–860CrossRef

51.

Keerthivasan S, Keerthivasan G, Mittal S, Chauhan SS (2007) Transcriptional upregulation of human cathepsin L by VEGF in glioblastoma cells. Gene 399(2):129–136PubMedCrossRef

52.

Ouyang L, Shi Z, Zhao S, Wang FT, Zhou TT, Liu B et al (2012) Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis. Cell Prolif 45(6):487–498PubMedCrossRef

53.

Melo-Lima S, Celeste Lopes M, Mollinedo F (2014) Necroptosis is associated with low procaspase-8 and active RIPK1 and -3 in human glioma cells. Oncoscience 1(10):649–664PubMedPubMedCentralCrossRef

54.

Kang TB, Yang SH, Toth B, Kovalenko A, Wallach D (2014) Activation of the NLRP3 inflammasome by proteins that signal for necroptosis. Methods Enzymol 545:67–81PubMedCrossRef

55.

Reardon DA, Wucherpfennig KW, Freeman G, Wu CJ, Chiocca EA, Wen PY et al (2013) An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma. Expert Rev Vaccines 12(6):597–615PubMedPubMedCentralCrossRef

56.

Stupp R, Wong ET, Kanner AA, Steinberg D, Engelhard H, Heidecke V et al (2012) NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer 48(14):2192–2202PubMedCrossRef

57.

Turk B, Turk V (2009) Lysosomes as “suicide bags” in cell death: myth or reality? J Biol Chem 284(33):21783–21787PubMedPubMedCentralCrossRef

58.

Blomgran R, Zheng L, Stendahl O (2007) Cathepsin-cleaved Bid promotes apoptosis in human neutrophils via oxidative stress-induced lysosomal membrane permeabilization. J Leukoc Biol 81(5):1213–1223PubMedCrossRef

59.

Racoma IO, Meisen WH, Wang QE, Kaur B, Wani AA (2013) Thymoquinone inhibits autophagy and induces cathepsin-mediated, caspase-independent cell death in glioblastoma cells. PLoS One 8(9):e72882PubMedPubMedCentralCrossRef

60.

Boya P, Kroemer G (2008) Lysosomal membrane permeabilization in cell death. Oncogene 27(50):6434–6451PubMedCrossRef

Titel: How to train glioma cells to die: molecular challenges in cell death
verfasst von: Jeffrey Wojton
Walter Hans Meisen
Balveen Kaur
Publikationsdatum: 01.02.2016
Verlag: Springer US
Erschienen in: Journal of Neuro-Oncology / Ausgabe 3/2016
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-015-1980-1

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2016

Progression-free and overall survival in patients with recurrent Glioblastoma multiforme treated with last-line bevacizumab versus bevacizumab/lomustine

Pseudoprogression in glioblastoma patients: the impact of extent of resection

Presurgical navigated TMS motor cortex mapping improves outcome in glioblastoma surgery: a controlled observational study

Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas

TERT promoter mutations and rs2853669 polymorphism: prognostic impact and interactions with common alterations in glioblastomas